Quilizumab

Quilizumab (Anti-Human IGHE Recombinant Antibody) is a humanized IgG1κ monoclonal antibody targeting immunoglobulin epsilon (also konwn as: IGHE, IgE). Quilizumab targets the M1-prime fragment of membrane-expressed IGHE/IgE, leading to IGHE/IgE switching and memory B cell depletion. Quilizumab has potential in asthma research[1].

[1] Jeffrey M Harris, et al. A randomized trial of the efficacy and safety of quilizumab in adults with inadequately controlled allergic asthma. Respir Res. 2016 Mar 18;17:29. DOI:10.1186/s12931-016-0347-2